Richard A. Young, Ph.D.
Director at Dewpoint Therapeutics.
Raised on Dewpoint Therapeutics filings
$77.2M
of $82.3M offered across 1 Form D filing
- Form D filings
- 1
- Teammates
- 10
- Last filing
- Jul 13, 2026
Company
Small-molecule drugs that target biomolecular condensates
- Investors
- 23
- Still open
- $5.1M
Dewpoint Therapeutics filings
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jul 13, 2026 | Equity | $77.2M/ $82.3M | Form D/A |
- EquityFiled Jul 13, 2026Form D/A$77.2M/ $82.3M
Works with
Ameet NathwaniPresident and Chief Executive Officer, Form D signerForm D signerIsaac Klein, M.D., Ph.D.Executive OfficerMark MurckoDirectorAmir H. Nashat, Sc.D.DirectorAnthony A. Hyman, Ph.D.DirectorGiuseppe A. Ciaramella, Ph.D.DirectorOlivier Brandicourt, M.D.DirectorRegina Barzilay, Ph.D.DirectorSrinivas Akkaraju, M.D., Ph.D.DirectorSteven Neier, Ph.D.Director
